Suchergebnisse - "Sail, Kavita"

PubPharm (42)

1

Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia : analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

enthalten in: The Lancet. Oncology | 2024

von Kater, A. | Arslan, �. | Demirkan, F. | +24

2

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings : Results From a Multi-Center International Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Shadman, M. | Manzoor, B. | Sail, K. | +28

3

Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI) : stakeholder views, objectives, and procedures

enthalten in: The Lancet. Oncology | 2023

von Pe, M. | Alanya, A. | Falk, R. | +125

4

Single-arm studies involving patient-reported outcome data in oncology : a literature review on current practice

enthalten in: The Lancet. Oncology | 2023

von Liu, L. | Choi, J. | Musoro, J. | +54

5

A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada

enthalten in: PharmacoEconomics - open | 2023

von Chatterjee, A. | van de Wetering, G. | Goeree, R. | +5

6

Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma

enthalten in: Journal of comparative effectiveness research | 2023

von Miller, S. | Lozano-Ortega, G. | Mutebi, A. | +4

7

A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada

enthalten in: PharmacoEconomics - open | 2022

von Chatterjee, A. | van de Wetering, G. | Goeree, R. | +5

8

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

enthalten in: Blood advances | 2022

von Thompson, M. | Harrup, R. | Coombs, C. | +35

9

Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia : results from the phase 3b VENICE II trial

enthalten in: Leukemia & lymphoma | 2022

von Cochrane, T. | Enrico, A. | Gomez-Almaguer, D. | +12

10

Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States

enthalten in: Journal of managed care & specialty pharmacy | 2021

von Chatterjee, A. | Shapouri, S. | Manzoor, B. | +5

1
2
3
4
5
Nächster »
[5]